EO
Therapeutic Areas
Bessor Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Immuno-Oncology Program | Hard-to-treat tumors (e.g., melanoma, pancreatic cancer) | Pre-clinical |
| Inflammation Program | Acute Kidney Injury, COVID-19 injury, pancreatitis, chemotherapy tissue damage | Pre-clinical |
| Chemical Synthesis Platform | Platform/Technology | Research |
Leadership Team at Bessor Pharma
AG
Anthony G.M. Barrett, FRS, FMedSci
VP Chemistry
AM
Allan M. Cohen, Esq., CPA
Chief Executive Officer
MR
Mark Roffman, PhD
VP Drug Development and Regulatory Affairs
RG
Robert Gottlieb
Advisor, Strategy and Messaging
MD
Martin D Hynes III, PhD
VP Project Management and Quality Assurance
BA
Barry A. Berkowitz, PhD
Founder and Chairman
MG
Marc Goldberg, JD, MBA
Board Member, Managing Partner, BioVentures Investors
EJ
E. Jonathan Soderstrom, PhD
Chief Licensing Advisor